DP
EWTX icon

Diadema Partners’s Edgewise Therapeutics EWTX Stock Holding History

Diadema Partners’s Portfolio EWTX Stock Details EWTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-212,500
Closed -$6.69M – 164
2026
Q1 		$6.69M Buy
+212,500
New +$6.13M 1.14% 31
2025
Q2 		– Sell
-98,200
Closed -$2.16M – 110
2025
Q1 		$2.16M Buy
+98,200
New +$2.58M 0.56% 42

Other funds holding EWTX

O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Diadema Partners's EWTX Position: Q2 2026 in Review

Diadema Partners opened a new position in Edgewise Therapeutics (EWTX) in Q2 2026: 272,214 shares worth $11.1M. The stake represents 1.4% of the portfolio and ranks #23 among its holdings. This is a return to the name: Diadema Partners previously reported a position in EWTX as recently as Q4 2025.

Diadema Partners first reported a position in EWTX in Q4 2024 and has held it in 3 quarters since. 227 funds tracked by Wall St. Rank hold EWTX as of Q2 2026.

  • Diadema Partners held 272,214 shares of Edgewise Therapeutics worth $11.1M as of Q2 2026.
  • Edgewise Therapeutics was a new Diadema Partners position in Q2 2026.
  • Edgewise Therapeutics made up 1.4% of Diadema Partners's portfolio in Q2 2026, its #23 holding.
  • Diadema Partners first reported a position in Edgewise Therapeutics in Q4 2024 and has held it in 3 quarters since.
  • 227 funds tracked by Wall St. Rank held Edgewise Therapeutics as of Q2 2026.

Based on Diadema Partners's 13F filing for Q2 2026, filed 14 Aug 2026.